Efforts are needed to improve informed consent of participants in research. The Strategic Timing of AntiRetroviral Therapy (START) study provides a unique opportunity to study the effect of length and complexity of informed consent documents on understanding and satisfaction among geographically diverse participants.
Introduction
Informed consent is widely accepted as an integral part of ethical clinical research [1, 2] and includes three distinct elements: (1) disclosure of information to prospective research participants, (2) participant understanding of the information, and (3) a voluntary decision by the participant to enrol in the research. However, the goal of informed individuals making voluntary choices about research participation is often imperfectly realized. Data suggest that comprehension of important study information, especially side effects and randomization of treatment, varies considerably and can be unacceptably low [3] [4] [5] [6] [7] [8] [9] . In addition, some participants do not seem to understand that participation is their choice or that they can leave a study at any time [8, [10] [11] [12] [13] [14] .
Unfortunately, as more evidence emerges that comprehension is inadequate, written consent documents have become increasingly long and complex. Legal, ethical, regulatory, and risk reduction authorities have all had a hand in adding language to consent documents in the interests of 'protecting' the human participant as well as the research institution or sponsor.
Some groups have attempted to improve the consent process by improving the readability of consent documents [15] [16] [17] [18] [19] [20] . Studies that compared typical consent forms with more simplified designs (usually lower in reading level and sometimes shorter) have found either equivalency between the regular and simplified forms [15] [16] [17] or statistically and clinically significant improvements in comprehension with a simpler form [18, 19] . Studies that measured satisfaction found that participants clearly preferred the simplified forms [16, 17] .
In this report, we describe the characteristics of the sites and research participants that participated in the START Informed Consent Substudy, including consent procedures across sites.
Methods
The International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of AntiRetroviral Therapy (START) study [21] , a large international treatment strategy trial for antiretroviral-naïve HIV-positive individuals, provides an opportunity to compare participant understanding of a standard consent form with understanding of a more concise consent form, across a variety of languages and international research settings. Towards this end, participants consenting to START at sites participating in the START Informed Consent Substudy gave responses to questions regarding their satisfaction with and comprehension and voluntariness of the informed consent process. The primary endpoint is the proportion of participants giving correct answers to questions about randomization on a self-administered questionnaire. An important secondary endpoint will be based on composite scores on the comprehension section of the instrument that will include questions on study purpose and procedures, randomization, risks and side effects, and the right to refuse study participation. A comprehension score will be based on the number of correct answers to the knowledge questions. Other secondary endpoints will be measured by a composite score for the satisfaction questions, a composite score for the voluntariness questions, and a descriptive analysis of the changes made to the consent documents by each site's governing institutional review board (IRB)/ethics committee (EC).
All sites registering for START were invited to participate in the Informed Consent Substudy. The only criterion for a site's participation was that there be at least two sites participating in which individuals would be consenting primarily in the same language.
After the sample informed consent document (the 'standard' consent) for the START study was developed, the substudy protocol team prepared a second sample consent document in consultation with the main study protocol team. This 'concise' consent document contained all of the required and additional elements of informed consent [22] , but was considerably shorter (1821 words versus 5927 in the standard consent) and at a slightly lower reading grade level (Flesch Kincaid Grade Level 9.2) than the standard template (Flesch Kincaid Grade Level 10.3). The concise version simplified sentences, reduced repetition, and made extensive use of tables and bulleted lists to convey information, while the standard version was written in a typical prose style. Both consents also included language informing potential START participants that by reading and signing the consent they were participating in a study of the informed consent process and would be asked to complete a questionnaire about their experience. Participants were told they could decline the questionnaire without consequence to their participation in START or their regular medical care.
Sites that chose to participate in the Informed Consent Substudy submitted both consent versions to their governing IRBs/ECs after making any necessary site-specific changes. Sites were asked to keep changes to a minimum and to ask their IRBs/ECs to do the same. Site-specific consent pairs (standard and concise) would undergo central textual analyses to assure that they remained different from one another after modification. Upon approval by the governing IRB/EC of both consents, each participating site was randomized to use either the standard or the concise consent for all participants. Randomization was stratified by the primary language of consent at the site and done in blocks of two to assure balance between consent designs within each language.
The START Informed Consent Substudy is a clusterrandomized trial; the unit of randomization (between standard and concise consent documents) was the site rather than the individual participant. The cluster randomization strategy enhances the ability to compare the two consent documents and decreases the possibility that those obtaining consent will alter their usual process because of the substudy. Randomization by site also minimized the logistical burden at the site because the same consent form and process were utilized for each participant.
The substudy aim is to determine whether the concise consent is at least 'as good as' the standard consent. However, an odds ratio (OR) that indicates no statistically significant difference between groups does not necessarily mean that the response is similar in the two groups. A noninferiority approach will be taken in analysis to determine whether a nonsignificant OR indicates that the responses are similar enough to state that the concise consent provides sufficient understanding of study procedures compared with a standard consent. With a 7.5% noninferiority margin, the substudy has good power to make such a statement for the primary outcome (i.e. the proportion of participants understanding randomization in the concise consent group will not be more than 7.5% less than that in the standard consent group).
Sites were asked to have participants complete a selfadministered questionnaire immediately after signing the consent form for START and before discussion of any other substudies or randomization to START. The questionnaire had 26 items addressing the participant's experience with the consent process (e.g. Did you feel adequately informed? Did you feel any pressure to join?) and relationship with site staff (e.g. How long have you known the staff? How well did they explain the study to you?) and 16 items to assess the participant's understanding of the information in the consent, including questions about the mechanism of randomization and possible risks and benefits of participating. Basic demographic information on each participant and screening CD4 measurements, if available, were collected on the screening form that was completed for each participant who signed a consent form for START.
The staff member who obtained the participant's signature on the consent form completed a seven-item questionnaire about how the consent form was used and how much person-time was used for the entire process for that individual participant. A clinical research staff member with primary involvement in the START study at each site also completed a one-time 14-item survey describing the general process for obtaining participant consent to START at their site. Questions included whether and what additional written information was provided to participants, whether participants received the consent form before the visit at which they signed it, and how the site typically assessed participant understanding of the study at the end of the consent process.
Results
Of the 221 sites registered to participate in START, 157 opened to the substudy, and 154 ultimately participated in the substudy by obtaining consent for at least one person to participate in START. Of the 64 START sites that did not open to the substudy, 23 did so because of a policy-level decision by their funding group that ruled out participation in START substudies. About one-third (n = 14) of the remaining 41 sites that did not participate in the Informed Consent Substudy did so because they did not have a language in common with another participating site (such as the single site in Nigeria, where the patient base speaks Hausa). However, this was not the only factor limiting participation. For example, in Sweden, where two sites enrolled participants into START, regulations strictly limit the length of informed consent documents to less than the length of our concise consent template. While 'participant information sheets' may be used to supplement the consent document, the length of these is also strictly limited, and so no meaningful difference between the standard and concise consents would be possible in Sweden. The START study's two-stage site start-up process (beginning enrolment at 101 pilot sites, then adding 120 new sites to complete the trial) was also a limiting factor as many of the sites that had not been part of the pilot did not want the delay in enrolment that may have occurred with participation in substudies.
Even though 14 of the 35 countries participating in START did not participate in the Informed Consent Substudy, the distribution of sites by geographical region and by number of participants consenting and randomized to START is similar to that for all sites participating in START [23] ; most sites were located in Europe (43%), North America (28%) or South America/Mexico (14%). The geographical and language distribution of the 154 sites and 4473 individuals participating in the Informed Consent Substudy are shown in Table 1 . Sites in South America and in Africa tended to be very high-enrolling sites in START, and together enrolled over half (53%) of the participants in the substudy, despite representing only 16% of the sites. This was also reflected in the primary language of consent identified for each site, with almost half of substudy enrolment (49%) occurring at sites that identified with a consent language used in South America (Spanish or Portuguese) or Africa (Luganda).
The level of HIV research experience and aspects of the consent processes used at participating sites are described in Table 2 . Sites with more HIV studies enrolled higher numbers of participants; the 24% of sites that have had more than 10 HIV studies ongoing in the past year enrolled 37% of the participants in the Informed Consent Substudy. The majority of sites (64%) provided written information in advance of the visit at which the participant signed a consent form for START. Among the sites providing written information in advance, 88% provided the consent document as part of that information. A majority (56%) of all sites provided the consent document to participants in advance of the visit at which the consent form was signed.
Site leaders, study investigators of record, coinvestigators, study coordinators, nurses, and other research staff were all active participants in the consent process, and in the majority of sites (58%), an investigator was the individual who obtained the participant's signature on the consent document. Sites spent anywhere from 15 min to 3 h in the consent process with each participant, with approximately half of the sites reporting less than 1 h spent and the other half reporting more than 1 h spent ( Table 2 ). In the vast majority of sites (81%) the participant's understanding of the study was assessed interactively, with specific (8%) or general (73%) questions about understanding asked of the participant before the signature was obtained.
Demographic information and baseline CD4 cell count for participants in the substudy are found in Table 3 . The proportion of individuals signing the consent form who were subsequently randomized to START (80%) was almost exactly the same in participants in the substudy as in all individuals consenting to participate in START, and demographic characteristics (age, race, gender and education) were similar to those of the entire randomized START cohort [23] . CD4 cell counts for participants in the Informed Consent Substudy were also similar to those for participants randomized to START.
Conclusions
These data indicate strong support to participate in this substudy within the INSIGHT network. Not only is this support evidence that the INSIGHT trial staff share a commitment to be involved actively in the consent process alongside potential trial participants, but it also reflects the concern shared by many researchers that the evolution of the consent document into its current form has not benefited potential research participants and may result in participants being less informed, not more, about the research in which they are being asked to take part. IRBs/ECs were generally supportive of the Informed Consent Substudy and willing to keep changes to a minimum as allowed within their own institutional guidelines. All site-approved consent documents were reviewed by the START study sponsor (the University of Minnesota) before a site was randomized in the substudy, and there was rarely any concern that local changes had substantially reduced the difference between the standard and concise consent forms. A qualitative and quantitative description of the specific changes made at the local level is planned for a future paper.
The Informed Consent Substudy of START is by far the largest study of an informed consent intervention ever conducted [24] . As a study with broad international scope, the results of this substudy have the potential to impact how consent forms are written around the world. It may provide hard evidence for countries that have already regulated the length of consent documents because of concerns that the consent process was becoming less beneficial to participants as documents increased in length and complexity.
The START study is registered at clinicaltrials.gov (NCT00867048).
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